BIOVECTRA is Honoured With 2025 CDMO Leadership Award, Biologics — Industry Recognizes BIOVECTRA’s Excellence in Microbial Fermentation, Recombinant Protein Production, and Aseptic Fill-Finish Capabilities.

Posted on by BIOVECTRA

CHARLOTTETOWN, Prince Edward Island – BIOVECTRA, a part of Agilent Technologies Inc., is a leading North American CDMO specializing in biologics, mRNA therapeutics, and complex chemistry, proudly announces it is the recipient of the 2025 Outsourced Pharma CDMO Leadership Award in the category of biologics. The award recognizes BIOVECTRA’s performance in key areas such as quality, reliability, and technical capability.

“We are thrilled to introduce our 2025 CDMO Leadership Awards winners to the outsourcing community and honored to offer such an important tool for drug sponsors in selecting their best-fit partner to help bring life-saving therapies to market,” said Louis Garguilo, chief editor at Outsourced Pharma. “The new categories and enhanced scoring methodology that went into this year’s appraisal bring an improved experience for drug sponsors using the resource as well as an ever-so-coveted distinction for the CDMOs. The unveiling of the award champions during our celebration in March will be an exciting new addition to the festivities.”

For the last fourteen years, the CDMO Leadership Awards have recognized top-performing contract development and manufacturing organizations based on industry research and sponsor feedback and offers drug developers insight into highly rated outsourcing partners.

“This award is a testament to BIOVECTRA / Agilent’s deep commitment to a client-first approach rooted in scientific excellence and manufacturing solutions,” said Brian Carothers, Vice President and General Manager, Advanced Manufacturing Partnerships Division, Agilent Technologies. “We are honored that our team’s dedication to advancing biologics manufacturing and setting new standards is being recognized among industry leaders. From process development through to commercial-scale production, we remain focused on delivering high-quality biomanufacturing solutions that support accelerating our clients’ path to market.”

BIOVECTRA will celebrate this achievement alongside fellow award recipients at the CDMO Leadership Awards ceremony in New York City on March 19, 2025.

BIOVECTRA supports clients across the biologics supply chain with advanced capabilities and expertise in microbial fermentation, protein purification, and single-use bioprocessing technologies. Its’ GMP-certified facilities provide clinical-to-commercial scale manufacturing including aseptic Fill Finish capabilities for injectable therapies. The company’s investment in advanced biomanufacturing technologies and flexible production infrastructure enable drug sponsors to streamline development timelines while maintaining regulatory compliance.

For more information on BIOVECTRA’s clinical-to-commercial scale capabilities and services, please visit www.biovectra.com. Pharmaceutical developers interested in leveraging these advanced biomanufacturing capabilities for their next project are encouraged to contact the company’s expert team online.

About BIOVECTRA
BIOVECTRA is a part of Agilent, a leader in clinical and analytical lab technologies and specialized CDMO services. With operations in Atlantic Canada BIOVECTRA specializes in clinical-to-commercial scale production capabilities for biologics, synthetic small molecules, highly potent APIs, and bioreagents. Its expertise has expanded into pDNA and mRNA vaccine manufacturing. Currently it employs close to 700 people across a variety of roles in science, quality, manufacturing and production, and business administration.

BIOVECTRA Media Contact

Bobbi Jo Walker
Director, Corporate Communications
[email protected]
902-218-7649

SEO plus – Test

  • 20+ years at GSK, leading R&D activities on multiple vaccine programs
  • Recently held positions in industry include: Senior Director (Function Head), Protein Biochemistry; Director, Antigen Design & Prototype Production; and, Associate Director, Antigen Design and Protein Characterization.
  • Key areas of expertise are:
    • Process development of protein Biologics/Recombinant Antigens
    • Recombinant protein expression (mammalian, insect, yeast, bacterial)
    • Production/design of Viral Vectors, mRNA vaccines, Bacterial outer membrane vesicles
    • Protein Engineering and Structural Biology
    • Defining quality attributes, biophysical characterization of proteins, and analytical strategy
  • Post graduate degrees in Functional Genomics (Université Laval) and Bioinformatics (MIT); M. Sc. Microbiology and Immunology (Laval).
  • 25+ Patent & 5 Scientific Publications

Normand Blais – Senior Director Development & Innovation, Biologics

  • 20+ years at GSK, leading R&D activities on multiple vaccine programs
  • Recently held positions in industry include: Senior Director (Function Head), Protein Biochemistry; Director, Antigen Design & Prototype Production; and, Associate Director, Antigen Design and Protein Characterization.
  • Key areas of expertise are:
    • Process development of protein Biologics/Recombinant Antigens
    • Recombinant protein expression (mammalian, insect, yeast, bacterial)
    • Production/design of Viral Vectors, mRNA vaccines, Bacterial outer membrane vesicles
    • Protein Engineering and Structural Biology
    • Defining quality attributes, biophysical characterization of proteins, and analytical strategy
  • Post graduate degrees in Functional Genomics (Université Laval) and Bioinformatics (MIT); M. Sc. Microbiology and Immunology (Laval).
  • 25+ Patent & 5 Scientific Publications

Oliver Technow - Chief Executive Officer

  • Industry Master Degree from Frankfurt Chamber of Commerce, Frankfurt Germany.
  • More than 20 years of global pharmaceutical industry experience.
  • Held numerous leadership positions in commercial development, marketing and brand management, and lifecycle management and has extensive product launch and market access expertise in Europe and North America.
  • In 1997, joined Eisai GmbH in Frankfurt, Germany and in 2002, was appointed Director, CNS Business Unit; in 2006, was appointed Vice President, Head of Global Marketing for Eisai Inc. in Woodcliff Lake, NJ;  in 2011, was appointed Vice President, Established Products Business Unit; in 2013, was appointed President & General Manager for Eisai Limited in Mississauga, ON.
  • Appointed President of BIOVECTRA Inc., December 10, 2015.
  • Board Director for BIOTECanada
  • Member of the Steering Council of Innovative Medicines Canada (IMC)
  • In 2017, appointed to the Government of Canada’s Health/Bio-sciences Strategic Economic Table
  • In November 2019, promoted to Chief Executive Officer at BIOVECTRA
  • In June 2020, named new Chair of PEI BioAlliance Board of Directors